🔖
Cite This Article
TARIQ, H., ZAHRA, U. (2022). Pseudo-Kappa Light Chain Restricted Hematogones in Patients Receiving Daratumumab. Turkish Journal of Hematology, Cilt: 39 - Sayı: 1, 80–81. https://ajindex.com/articles/411525
Journals / Turkish Journal of Hematology / 2022 / Cilt: 39 - Sayı: 1
Pseudo-Kappa Light Chain Restricted Hematogones in Patients Receiving Daratumumab
- Pages
- 80–81
- DOI
- —
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗References (5)
- Deneys V, Thiry C, Frelik A, Debry C, Martin B, Doyen C. Daratumumab: Therapeutic asset, biological trap! Transfus Clin Biol 2018;25:2-7
- Moore LM, Cho S, Thoren KL. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins. Clin Chim Acta 2019;492:91-94
- Nooka AK, Kaufman JL, Hofmeister CC, Joseph NS, Heffner TL, Gupta VA, Sullivan HC, Neish AS, Dhodapkar MV, Lonial S. Daratumumab in multiple myeloma. Cancer 2019;125:2364-2382
- Jiang XY, Luider J, Shameli A. Artifactual kappa light chain restriction of marrow hematogones: a potential diagnostic pitfall in minimal residual disease assessment of plasma cell myeloma patients on daratumumab. Cytometry B Clin Cytom 2020;98:68-74
- Chantepie SP, Cornet E, Salaün V, Reman O. Hematogones: an overview. Leuk Res 2013;37:1404-1411.